Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Outlook For Lilly’s Cialis In China

This article was originally published in PharmAsia News

Executive Summary

Lilly's second quarter results for 2008 show that Cialis (tadalafil) sales increased 24 percent to $362 million globally. Revenue hit $1.2 billion in 2007, closing the gap between Pfizer's Viagra sales of $1.8 billion. However, according to Lilly China officials, the drug has only broken even after six years in the country, and just starting to turn a profit now. Though Cialis sales in China only account for less than 1 percent of Lilly's worldwide revenue, the country's almost 30 percent growth makes it greatly attractive when compared with the single-digital growth for most markets. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel